Day One Biopharmaceuticals Inc
DAWN
Financials
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Day One Biopharmaceuticals is a clinical-stage oncology company whose core business model requires animal testing for drug development and regulatory approval. As a biopharmaceutical enterprise, its research pipeline is built on preclinical studies that, by current scientific and regulatory necessity, involve animal models. The company’s exclusive license from Merck KGaA to develop and commercialize pharmaceutical compounds inherently relies on this standard industry practice. While the broader pharmaceutical sector engages in efforts to replace, reduce, and refine animal work, the fundamental reliance on animal data for initial safety and efficacy profiling remains a baseline requirement for bringing new drugs to market. This places the company within the category of enterprises whose commercial existence is predicated on the use of animals in research.
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company whose business model inherently requires animal testing for regulatory approval. The company’s lead product, tovorafenib (Ojemda), received accelerated FDA approval in April 2024. The FDA’s approval review documents explicitly cite animal studies as part of the basis for that approval, noting findings from these studies informed the drug’s safety profile and mechanism of action. As a developer of novel cancer therapies, Day One’s preclinical and clinical development pipeline is subject to FDA regulations that mandate animal testing to demonstrate safety and efficacy before human trials can proceed.
Research Sources
9 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.